Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice (Q39198588)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 February 2013

Language	Label	Description	Also known as
English	Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice	scientific article published on 26 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

K Hunter

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

I A Montgomery

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

26 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

650-659

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

What do we know about the secretion and degradation of incretin hormones?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

The future of incretin-based therapy: novel avenues--novel targets

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

The biology of cholecystokinin and gastrin peptides

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Inconsistency and possible habituation of CCK-induced satiety.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

CCK stimulation of GLP-1 neurons involves α1-adrenoceptor-mediated increase in glutamatergic synaptic inputs

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Rapid development of tolerance to the behavioural actions of cholecystokinin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12079

21 January 2018

Identifiers

10.1111/DOM.12079

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39198588&oldid=1812517650"